Literature DB >> 9932955

Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis?

C Demerens1, B Stankoff, B Zalc, C Lubetzki.   

Abstract

OBJECTIVE: To examine the potential of eliprodil-a neuroprotective agent with a high affinity for sigma-receptors-to promote myelination in neuron-oligodendrocytes cocultures.
BACKGROUND: Remyelination is one of the major therapeutic issues in MS. Because neuronal integrity is required for CNS myelination, the authors postulated that neuroprotective molecules might favor myelination.
METHODS: Two experimental culture conditions were compared: standard medium Bottenstein and Sato ([B-S] medium) and a medium depleted of both thyroid hormones and progesterone (depleted [D] medium). Myelination was quantified by counting the number of myelinated internodes, identified immunocytochemically with an antimyelin basic protein (anti-MBP) antibody.
RESULTS: The authors first confirmed that in D medium myelination was reduced by a factor of 3.5 compared with cultures maintained in B-S medium. Under both culture conditions, addition of 10(-6) M eliprodil did not modify significantly the total number of either microtubule associated protein-2-positive neurons or MBP-positive oligodendrocytes. However, eliprodil induced a twofold (p < 0.01) increase in myelination when added to B-S medium, and a 4.7-fold (p < 0.0001) increase when added to D medium.
CONCLUSION: Although the molecular mechanism mediating the effect of the sigma-receptor agonist on myelination remains to be elucidated, these results strongly suggest that neuroprotective molecules may be of therapeutic interest in demyelinating diseases such as MS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9932955     DOI: 10.1212/wnl.52.2.346

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Molecular imaging of σ receptors: synthesis and evaluation of the potent σ1 selective radioligand [18F]fluspidine.

Authors:  Steffen Fischer; Christian Wiese; Eva Grosse Maestrup; Achim Hiller; Winnie Deuther-Conrad; Matthias Scheunemann; Dirk Schepmann; Jörg Steinbach; Bernhard Wünsch; Peter Brust
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-12       Impact factor: 9.236

2.  The sigma receptor: evolution of the concept in neuropsychopharmacology.

Authors:  T Hayashi; Tp Su
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

3.  Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation.

Authors:  S Liu; Y Qu; T J Stewart; M J Howard; S Chakrabortty; T F Holekamp; J W McDonald
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

4.  High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis.

Authors:  B Oxombre; C Lee-Chang; A Duhamel; M Toussaint; M Giroux; M Donnier-Maréchal; P Carato; D Lefranc; H Zéphir; L Prin; P Melnyk; P Vermersch
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

5.  Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites.

Authors:  Renaud Schoemans; Marie-Stéphane Aigrot; Chaohong Wu; Raphaël Marée; Pengyu Hong; Shibeshi Belachew; Claire Josse; Catherine Lubetzki; Vincent Bours
Journal:  J Inherit Metab Dis       Date:  2010-02-12       Impact factor: 4.982

6.  Decreased spinal cord opioid receptor mRNA expression and antinociception in a Theiler's murine encephalomyelitis virus model of multiple sclerosis.

Authors:  Jessica L Lynch; Jeremy F Alley; Lori Wellman; Alvin J Beitz
Journal:  Brain Res       Date:  2007-11-28       Impact factor: 3.252

7.  Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-04       Impact factor: 11.205

8.  Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis.

Authors:  Bénédicte Oxombre; Fahima Madouri; Anne-Sophie Journé; Séverine Ravez; Eloise Woitrain; Pascal Odou; Nathalie Duhal; Sandro Ninni; David Montaigne; Nadira Delhem; Patrick Vermersch; Patricia Melnyk
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

9.  Drug Screening Identifies Sigma-1-Receptor as a Target for the Therapy of VWM Leukodystrophy.

Authors:  Andrea Atzmon; Melisa Herrero; Reut Sharet-Eshed; Yocheved Gilad; Hanoch Senderowitz; Orna Elroy-Stein
Journal:  Front Mol Neurosci       Date:  2018-09-18       Impact factor: 5.639

Review 10.  Sigma receptors and neurological disorders.

Authors:  Agnieszka Piechal; Alicja Jakimiuk; Dagmara Mirowska-Guzel
Journal:  Pharmacol Rep       Date:  2021-08-05       Impact factor: 3.024

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.